Dublin, April 01, 2026 (GLOBE NEWSWIRE) — The “Doxorubicin Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
This analysis provides a comprehensive perspective on the doxorubicin market, elucidating key trends, growth prospects, and the strategic actions of leading pharmaceutical firms. With a focus on innovation and expanding treatment coverage, the market is poised to address the increasing needs of the oncology sector effectively.
The doxorubicin market is experiencing robust growth, projecting an increase from $1.42 billion in 2025 to $2 billion by 2030, at a CAGR of 7.2%. This expansion is driven by rising cancer prevalence, enhanced clinical adoption of anthracyclines, and expanded hospital oncology infrastructure. Key factors fostering growth include rising demand for cost-effective oncology treatments and the evolution of liposomal and targeted drug delivery systems. Increased access to cancer therapies in developing regions and approvals of generic formulations further bolster this upward trajectory.
Doxorubicin is a key chemotherapeutic agent known for its efficacy in treating various cancer types. The drug’s growing prominence is attributed to the increasing cancer incidence globally. In 2024, the American Cancer Society reports a projected rise to approximately 2 million new cancer cases in the U.S. alone, heightening the demand for doxorubicin-based treatments.
Leading pharmaceutical companies are focusing on innovation to enhance chemotherapy treatment efficacy, reduce adverse effects, and improve patient outcomes. Lupin Limited’s introduction of Doxorubicin Hydrochloride Liposome Injection marks a significant step in advanced drug delivery systems, focusing on cancer types like advanced ovarian cancer and AIDS-related Kaposi’s sarcoma. These innovations aim to improve targeted delivery and reduce systemic toxicity.
Strategic acquisitions are shaping the competitive landscape. Johnson & Johnson’s acquisition of Ambrx Biopharma, valued at around $2 billion, underscores its commitment to advancing antibody-drug conjugates for prostate cancer.
The major players in the doxorubicin market include Pfizer Inc., Johnson & Johnson, Baxter International Inc., Teva Pharmaceutical Industries Ltd., among others. These companies are expanding their portfolios and investing in research to develop next-generation cancer therapies.
Regionally, North America led the market in 2025, with Asia-Pacific anticipated to be the fastest-growing region.
Reasons to Purchase:
- Access the most comprehensive report on the doxorubicin market across 16 geographies for a holistic global perspective.
- Analyze the effects of macro factors such as geopolitical dynamics, trade policies, inflation, interest rate changes, and regulatory shifts.
- Develop regional and national strategies grounded in localized data and evaluation.
- Spot growth segments ripe for investment.
- Surpass market competitors by leveraging forecast data and understanding the drivers and trends steering the market.
- Gain insights into end-user behavior for better customer understanding.
- Benchmark against key competitors using market share, innovation, and brand strength metrics.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to gauge market potential.
- Utilize data-rich and reliable insights for internal and external presentations.
- Stay updated with the latest market data delivered alongside an Excel data sheet for effortless extraction and analysis.
- Receive all report data in a user-friendly Excel dashboard format.
Markets Covered: Drug formulations, applications, and distribution channels.
Key Companies: Includes Pfizer, Johnson and Johnson, Baxter International, and more.
Countries: Coverage of regions such as Australia, China, Germany, India, and the USA, among others.
Regions: Includes Asia-Pacific, Western Europe, North America, etc.
Time Series: Offers five-year historical data and ten-year forecast.
Data: Details on ratios, GDP correlations, and expenditure per capita.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $1.52 Billion |
| Forecasted Market Value (USD) by 2030 | $2 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
The companies featured in this Doxorubicin market report include:
- Pfizer Inc.
- Johnson and Johnson
- Baxter International Inc.
- Teva Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Cipla Limited
- Hikma Pharmaceuticals
- Mylan Pharmaceuticals Inc.
- Accord Healthcare Ltd.
- TTY Biopharm Company Limited
- Cadila Pharmaceuticals
- Neon Laboratories Limited
- APP Pharmaceuticals Manufacturing LLC
- Sun Pharmaceutical Industries Ltd.
- Transo-Pharm Handels GmbH
- LGM Pharma
- Zhejiang Hisun Pharma
- Actavis Pharma
- Celon Laboratories Limited
- Samarth Life Sciences Pvt. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/tksg1c
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
